Raymond James Financial
VIR icon

Raymond James Financial’s Vir Biotechnology VIR Stock Holding History

Raymond James Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Buy
+12,333
New +$98.3K ﹤0.01% 5013
2025
Q3 		– Sell
-7,018
Closed -$35.4K – 6727
2025
Q2 		$35.4K Buy
+7,018
New +$37.6K ﹤0.01% 5321

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Raymond James Financial's VIR Position: Q1 2026 in Review

Raymond James Financial opened a new position in Vir Biotechnology (VIR) in Q1 2026: 12,333 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #5013 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in VIR as recently as Q2 2025.

Raymond James Financial first reported a position in VIR in Q2 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Raymond James Financial held 12,333 shares of Vir Biotechnology worth $111K as of Q1 2026.
  • Vir Biotechnology was a new Raymond James Financial position in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5013 holding.
  • Raymond James Financial first reported a position in Vir Biotechnology in Q2 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.